A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

As Silicon Valley entrepreneur Peter Thiel once wrote, "Competition is for losers." When a firm enjoys little competition, it ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

AT&T (T) is seeing a 6% surge in its stock price during midday trading following a strong set of Q4 results, reflecting ...

On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.

"attachment_1199023" align="aligncenter" width="1456"] An elderly couple receiving insulin from a pharmacist, representing ...

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

Here are some of the major companies whose stocks moved on the week’s news.